Enifrav

Enifrav is a prescription medication containing warfarin sodium as its active ingredient, provided in an oral dosage form with strength not specified on the label. It belongs to the anticoagulant class of drugs, specifically vitamin K antagonists, and is marketed in the European Union. It is used under medical supervision to reduce the risk of blood clots in various cardiovascular conditions. Patients should follow regular monitoring.

Enifrav is indicated for several thromboembolic disorders where anticoagulation is required.

- Prevention and treatment of venous thromboembolism (deep‑vein thrombosis and pulmonary embolism). - Prophylaxis of stroke and systemic embolism in patients with non‑valvular atrial fibrillation. - Prevention of thromboembolic complications in individuals with mechanical heart valve prostheses. - Long‑term anticoagulation in patients with recurrent clotting disorders as determined by a physician.

Side effects of Enifrav vary in frequency and severity; they are categorized as common and serious.

Common: - Minor bruising or bleeding from gums, nose, or cuts. - Small amounts of blood in urine or stool. - Nausea, abdominal discomfort, or loss of appetite. - Skin rash or mild itching. - Dizziness or light‑headedness.

Serious: - Significant bleeding such as gastrointestinal hemorrhage or intracranial bleed. - Severe allergic reaction with swelling of the face, lips, or throat. - Unexplained drop in hemoglobin or hematocrit levels. - Purple or black discoloration of the skin (purpura). - Rapid drop in blood pressure (hypotension) due to bleeding.

Before initiating Enifrav, clinicians evaluate several precautionary factors to minimize bleeding risk and ensure safe use.

- Baseline assessment of INR or PT/INR values and regular monitoring during therapy. - Evaluation of liver function, as impaired hepatic metabolism can increase drug exposure. - Review of patient history for prior hemorrhagic events, gastrointestinal ulcers, or intracranial bleeding. - Consideration of age, renal function, and concomitant use of antiplatelet agents. - Education on signs of bleeding and instructions to avoid activities that may cause trauma. - Pregnancy and lactation status should be assessed, as warfarin crosses the placenta.

Enifrav interacts with many medications; some combinations should be avoided, while others require careful dose adjustment and monitoring.

Avoid: - Strong CYP2C9 inhibitors such as fluconazole, amiodarone, and certain macrolide antibiotics. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin that increase bleeding risk. - Antiplatelet agents like clopidogrel or ticagrelor without close supervision.

Use with caution: - Vitamin K‑rich foods or supplements that may reduce anticoagulant effect. - Other anticoagulants (e.g., heparin, direct oral anticoagulants) when transitioning therapy. - Herbal products such as ginkgo biloba, garlic, or St. John’s wort that can affect coagulation.